Secukinumab has excellent effects on the signs and symptoms of psoriatic arthritis (PsA). McInnes and colleagues further analysed the effects of this drug on pain relief in the FUTURE 2 cohort. Pain was measured using three patient-reported measures (a pain visual analog scale, Short Form-36 bodily pain domain scores and EuroQol 5-Dimension 3-Level Questionnaire pain item scores). Secukinumab led to rapid and sustained pain relief, starting at week 3 and sustained through to 2 years. Improvements in pain were similar in patients who had or had not been exposed to TNF inhibitors.